SERSomes for metabolic phenotyping and prostate cancer diagnosis

Xinyuan Bi,Jiayi Wang,Bingsen Xue,Chang He,Fugang Liu,Haoran Chen,Linley Li Lin,Baijun Dong,Butang Li,Cheng Jin,Jiahua Pan,Wei Xue,Jian Ye
DOI: https://doi.org/10.1016/j.xcrm.2024.101579
2024-06-18
Abstract:Molecular phenotypic variations in metabolites offer the promise of rapid profiling of physiological and pathological states for diagnosis, monitoring, and prognosis. Since present methods are expensive, time-consuming, and still not sensitive enough, there is an urgent need for approaches that can interrogate complex biological fluids at a system-wide level. Here, we introduce hyperspectral surface-enhanced Raman spectroscopy (SERS) to profile microliters of biofluidic metabolite extraction in 15 min with a spectral set, SERSome, that can be used to describe the structures and functions of various molecules produced in the biofluid at a specific time via SERS characteristics. The metabolite differences of various biofluids, including cell culture medium and human serum, are successfully profiled, showing a diagnosis accuracy of 80.8% on the internal test set and 73% on the external validation set for prostate cancer, discovering potential biomarkers, and predicting the tissue-level pathological aggressiveness. SERSomes offer a promising methodology for metabolic phenotyping.
What problem does this paper attempt to address?